Accuray appoints Steve La Neve as CEO

Accuray (ARAY) Incorporated announced it is engaging in a significant organizational, strategic, and operational transformation. To accelerate this work, the company’s Board of Directors has appointed proven industry leaders with deep operational expertise to drive execution, strengthen performance, and enhance competitiveness. The Board has appointed Steve La Neve as CEO, effective October 20. He succeeds Suzanne Winter, who will retire after six years of service and remain in an advisory role through the end of November to ensure a seamless transition. La Neve brings more than 40 years of international medical-technology experience with a track record of driving margin expansion and revenue growth. He previously served as President of the Trauma and Joint Reconstruction business unit of Globus Medical Inc. and President of Globus Medical Japan K.K., Chief Executive Officer and Board Member of Bone Biologics Corporation, Global President of Becton Dickinson Preanalytical Systems, and as Global Sector President for Medtronic’s Spine and Biologics Division. To support the execution of the company’s transformation and growth strategy, the Board announced two additional leadership changes. Steven F. Mayer, who joined the Board in June 2025, has been appointed Transformation Board Sponsor and will partner closely with incoming CEO Steve La Neve and the management team to oversee execution of the company’s organizational, strategic and operational initiatives. In addition, Chan W. Galbato has been nominated to the Accuray Board of Directors.